On June 24, 2024, Teva launched the first generic version of Novo Nordisk's GLP-1 receptor agonist drug, liraglutide, known commercially as Victoza. This generic introduction marks a significant milestone in the diabetes and obesity medication market. The higher dose of 3mg daily, which is used for obesity, could potentially make the treatment more accessible to those in need. However, experts are cautious about immediate price reductions, citing market inertia and other factors.
Generic Liraglutide Is Here – Will It Make Any Difference? - ConscienHealth https://t.co/cPNSgUCPTY greed and inertia in this market are good descriptions
Generic Liraglutide Is Here – Will It Make Any Difference? - ConscienHealth https://t.co/9ZDjqHBTdd
Generic liraglutide is here. Will it lead to a moderation in pricing of diabetes and #ObesityMedicines? Maybe, but not right away. Here's why. https://t.co/6iDAsF57Dg
Generic #Liraglutide Is Here – Will It Make Any Difference? - @ConscienHealth https://t.co/970AOEUnLy
@Teva launches generic version of @novonordisk’s #diabetes GLP-1ra drug, liraglutide (#Victoza) | The higher dose of 3mg daily is the obesity version but perhaps the cost of this will help more people in need! https://t.co/moFwssJE7W
GLP1 Generics: It Has Begun Generic Liraglutide (Victoza) Becomes First Generic GLP-1 Receptor Agonist https://t.co/K354yv8qnH https://t.co/DgSEIuxu9C